Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FENNEC PHARMACEUTICALS INC.

(FENC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Fennec Pharmaceuticals : Earnings Flash (FRX.TO) FENNEC PHARMACEUTICALS Posts Net loss for Q2 was $4.0 million ($0.15 per share), compared to $4.8 million ($0.21 per share) for the same period in 202

08/10/2021 | 06:03am EST


ę MT Newswires 2021
All news about FENNEC PHARMACEUTICALS INC.
12/01Maxim Group Adjusts Price Target on Fennec Pharmaceuticals to $10 From $12, Keeps Buy R..
MT
11/30FENNEC PHARMACEUTICALS : Receives Complete Response Letter from the FDA for its New Drug A..
PU
11/30Craig-Hallum Adjusts Price Target on Fennec Pharmaceuticals to $14 From $19, Maintains ..
MT
11/30Fennec Pharmaceuticals Down 4% in US Pre-Market, Receives Complete Response Letter From..
MT
11/30Fennec Gets Official Notice of FDA Rejection of Pedmark
DJ
11/30FENNEC PHARMACEUTICALS BRIEF : Receives Complete Response Letter from the FDA for its New ..
MT
11/30Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug ..
AQ
11/30Fennec pharmaceuticals expects to receive complete response letter from the fda for its..
AQ
11/29Wedbush Maintains Outperform, US$9 TP, on Fennec Pharmaceuticals After Second Pedmark D..
MT
11/29WALL STREET STOCK EXCHANGE : Back to the guessing game
More news
Analyst Recommendations on FENNEC PHARMACEUTICALS INC.
More recommendations
Financials (USD)
Sales 2021 20,0 M - -
Net income 2021 6,55 M - -
Net Debt 2021 - - -
P/E ratio 2021 16,6x
Yield 2021 -
Capitalization 109 M 109 M -
Capi. / Sales 2021 5,45x
Capi. / Sales 2022 35,2x
Nbr of Employees 9
Free-Float 83,1%
Chart FENNEC PHARMACEUTICALS INC.
Duration : Period :
Fennec Pharmaceuticals Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FENNEC PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 4,19 $
Average target price 10,80 $
Spread / Average Target 158%
EPS Revisions
Managers and Directors
Rostislav C. Raykov Chief Executive Officer & Director
Robert C. Andrade Chief Financial Officer
Khalid Islam Chairman
Chris A. Rallis Independent Director
Adrian James Haigh Independent Director
Sector and Competitors
1st jan.Capi. (M$)
FENNEC PHARMACEUTICALS INC.-40.54%115
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.47%66 409
WUXI APPTEC CO., LTD.21.78%65 758
VERTEX PHARMACEUTICALS-13.76%51 819